India's Dr Reddy's beats Q3 profit estimates on strong US sales
In this article:
HYDERABAD, Jan 30 (Reuters) -
Indian pharmaceutical firm Dr Reddy's Laboratories beat estimates for third-quarter profit on Tuesday, helped by strong performance in its generic drugs business in key U.S. and European markets.
The Hyderabad-based company reported an 11% rise in consolidated net profit to 13.81 billion rupees ($166.17 million) for the quarter ended Dec. 31, compared with analysts' estimates of 12.77 billion rupees, according to LSEG data. ($1 = 83.1070 Indian rupees) (Reporting by Rishika Sadam in Hyderabad; Editing by Sonia Cheema and Anil D'Silva)
